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BACKGROUND & AIMS: We performed a genome-wide asso-
ciation study (GWAS) to identify genetic risk factors for drug-
induced liver injury (DILI) from licensed drugs without
previously reported genetic risk factors. METHODS: We per-
formed a GWAS of 862 persons with DILI and 10,588
population-matched controls. The first set of cases was
recruited before May 2009 in Europe (n ¼ 137) and the United
States (n ¼ 274). The second set of cases were identified fromMay 2009 through May 2013 from international collaborative
studies performed in Europe, the United States, and South
America. For the GWAS, we included only cases with patients of
European ancestry associated with a particular drug (but not
flucloxacillin or amoxicillin-clavulanate). We used DNA samples
from all subjects to analyze HLA genes and single nucleotide
polymorphisms. After the discovery analysis was concluded, we
validated our findings using data from 283 European patients
with diagnosis of DILI associated with various drugs. RESULTS:
We associated DILI with rs114577328 (a proxy for A*33:01 a
HLA class I allele; odds ratio [OR], 2.7; 95% confidence interval
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R[CI], 1.93.8; P ¼ 2.4  108) and with rs72631567 on chro-
mosome 2 (OR, 2.0; 95% CI, 1.62.5; P ¼ 9.7  109). The
association with A*33:01 was mediated by large effects for
terbinafine-, fenofibrate-, and ticlopidine-related DILI. The
variant on chromosome 2 was associated with DILI from a
variety of drugs. Further phenotypic analysis indicated that the
association between DILI and A*33:01 was significant genome
wide for cholestatic and mixed DILI, but not for hepatocellular
DILI; the polymorphism on chromosome 2 was associated with
cholestatic and mixed DILI as well as hepatocellular DILI. We
identified an association between rs28521457 (within the
lipopolysaccharide-responsive vesicle trafficking, beach and
anchor containing gene) and only hepatocellular DILI (OR, 2.1;
95% CI, 1.62.7; P ¼ 4.8  109). We did not associate any
specific drug classes with genetic polymorphisms, except for
statin-associated DILI, which was associated with rs116561224
on chromosome 18 (OR, 5.4; 95% CI, 3.09.5; P ¼ 7.1  109).
We validated the association between A*33:01 terbinafine- and
sertraline-induced DILI. We could not validate the association
between DILI and rs72631567, rs28521457, or rs116561224.
CONCLUSIONS: In a GWAS of persons of European descent
with DILI, we associated HLA-A*33:01 with DILI due to terbi-
nafine and possibly fenofibrate and ticlopidine. We identified
polymorphisms that appear to be associated with DILI from
statins, as well as 2 nondrug-specific risk factors.Keywords: Medication; Liver Damage; Side Effect; Anti-Fungal
Agent.
epatotoxicity is the second most common cause of*Authors share co-first authorship; §Authors share co-senior authorship.
Abbreviations used in this paper: AF, allele frequency; CM, cholestatic-
mixed; DILI, drug-induced liver injury; DILIN, Drug-Induced Liver Injury
Network; GWAS, genome-wide association study; HC, hepatocellular;
iDILIC, International Drug-Induced Liver Injury Consortium; LRBA,
lipopolysaccharide-responsive vesicle trafficking, beach and anchor
containing; MHC, major histocompatibility complex; OR, odd ratio; SNP,
single nucleotide polymorphism.
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marketing withdrawal,1 and idiosyncratic drug-induced
liver injury (DILI) accounts for 11%17% of cases of
acute liver failure in the United States and Europe.2,3 The
typical incidence of DILI varies from approximately 1% with
the anti-tumor necrosis factor agents4 to 0.04% with some
widely used antimicrobials such as amoxicillin-clavulanate.5
During the past 15 years, increasing progress on identifying
genetic risk factors for DILI has been made. In particular,
associations with HLA class I and II alleles have been
reported for DILI caused by a range of drugs, though a
particular HLA genotype does not appear to be relevant to
all forms of idiosyncratic DILI.6
Previously, a genome-wide association study (GWAS)
involving cohorts of DILI cases related to one particular
drug only resulted in identification of 1 or more drug-
specific HLA risk alleles.7–11 A large study involving 783
DILI cases due to a range of different drugs also resulted in
a genome-wide significant HLA signal, but this association
was abolished once 296 cases of DILI due to flucloxacillin
and amoxicillin-clavulanate were excluded.12 This partly
reflects the fact that amoxicillin-clavulanate is a very com-
mon cause of DILI worldwide and flucloxacillin is an equally
common cause in a number of Northern European
countries.13 Therefore, DNA collections from DILI cases
will generally be highly enriched in cases relating to these
2 drugs, making detection of associations related to other
compounds more difficult.We have expanded our previous study of DILI caused by
a range of different drugs,12 and after excluding cases
relating to amoxicillin-clavulanate and flucloxacillin, we
have more than doubled the number of cases, with additions
from Europe, Australia, South America, and the United
States. We now report that HLA-A*33:01 is associated with
risk of DILI, particularly due to terbinafine, fenofibrate, and
ticlopidine, and especially with a cholestatic or mixed
phenotype. We have also found novel nonmajor histo-
compatibility complex (MHC)-related signals apparently
shared across a range of different drugs; an intronic single
nucleotide polymorphism (SNP) in the lipopolysaccharide-
responsive vesicle trafficking, beach and anchor containing
(LRBA) gene is associated with hepatocellular DILI and an
intergenic SNP on chromosome 2, rs72631567, with DILI
generally. An additional drug-specific genome-wide signifi-
cant signal that could not be confirmed is also reported.
Materials and Methods
Drug-Induced Livery Injury Discovery Cohort
The cases in the study were from 2 separate recruitment
phases. Phase 1 consists of 411 cases included in a previous
study (from the Drug-Induced Liver Injury Network [DILIN],
DILIGEN, and Eudragene)12 and phase 2 more recently
recruited cases (n ¼ 451) of which a small subset was included
in a recent report.14
Phase 1 cases. These cases included 411 DILI cases not
due to amoxicillin-clavulanate or flucloxacillin, with a defined
casual drug and with causality score greater than possible
(Roussel Uclaf Causality Assessment Method score 3)
recruited in Europe (n ¼ 137) or the United States (n ¼ 274)
before 2009. Clinical characteristics of these cases and methods
used for genotyping have been described in detail previously.12
Additional exome chip analysis (Illumina Infinium Human-
CoreExome BeadChip) was performed on 150 of these 411
cases at the Broad Institute, Boston, MA.
Phase 2 case recruitment: International Drug-
Induced Liver Injury Consortium. The International
Drug-Induced Liver Injury Consortium (iDILIC) cases were
recruited between May 2009 and May 2013 as part of an
international collaborative study involving recruitment centers
in the United Kingdom (Newcastle, Nottingham, Liverpool,
London, Dundee), Sweden (Uppsala and Gothenburg), Spain
(Malaga and Barcelona), France (Montpellier), The Netherlands
(Utrecht), Germany (Kiel), Australia (Brisbane), Switzerland
(Zurich), Finland (Helsinki), Argentina (Rosario), Uruguay
(Montevideo), and Chile (Santiago). All participants provided
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by the appropriate national or institutional ethical review
boards. For the GWAS, only cases of European ancestry where
there were at least 2 cases due to a particular drug available
(when phase 1 cases from Europe and the United States
were also considered) and where the DILI was not due to
either flucloxacillin or amoxicillin-clavulanate were included
(n ¼ 339). Clinical inclusion criteria for all cases were those
described by Aithal et al.15
Phase 2 case recruitment: Drug-Induced Liver
Injury Network. Details of the US-based DILIN prospective
study including institutional review board approval informa-
tion have been described previously.16 A total of 112 eligible
new cases of European ancestry and 18 years and older were
included in the current GWAS. These new cases were selected
from the larger DILIN sample collection, such that only cases
relating to drugs also included among the iDILIC cases were
represented. Laboratory inclusion criteria were as described
previously.16 Patients were excluded if there was known or
suspected acetaminophen overdose, history of bone marrow
or liver transplantation before DILI onset, or history of
immune-related liver disease, such as autoimmune hepatitis.
Additional Cases Used for Confirmation of
Associations
After the discovery analysis was concluded, we enrolled an
additional 283 European patients with diagnosis of DILI across
multiple causal drugs (6 from iDILIC and 277 from DILIN
networks recruited subsequent to the GWAS). The causal drug
distribution is reported in Supplementary Table 1A. An addi-
tional 12 statin DILI samples from the Spanish iDILIC
network and 3 UK-DILIGEN cases were recruited later in the
study to confirm the class-specific association (Supplementary
Table 1B).
Of the 283, we used 272 DILI cases to directly type SNPs
associated across multiple drugs or specific for drugs and drug
classes and 11 DILI cases for HLA typing to confirm HLA
associations. An additional Chinese terbinafine DILI sample was
also HLA typed.
Causality Assessment
The iDILIC cases were evaluated by application of the
Council for International Organizations of Medical Science scale,
also called the Roussel Uclaf Causality Assessment Method15
and by expert review by a panel of 3 hepatologists. The
pattern of liver injury was classified according to the Interna-
tional Consensus Meeting Criteria.17 Only cases having at least
possible causality (score 3) were included in the study. For all
cases in DILIN, causality assessment was by expert consensus,
as described previously.16
Controls
Because DILI has a very low prevalence, we used general
population samples as study controls. We selected 10588
European ancestry controls from multiple available sources;
Welcome Trust Case Control Consortium (http://www.wtccc.
org.uk), the Population Reference Sample,18 PGX40001,19 and
Spanish Bladder cancer cohort (phs000346.v1) from dbGAP.20
In order to increase the casecontrol ratio for Italian, Span-
ish and Swedish, we added samples from Hypergenes cohort(http://www.hypergenes.eu/dissemination.html#pub), the Na-
tional Spanish DNA Bank (http://www.bancoadn.org/), Italian
Penicillin Tolerant Controls, and the Swedish Twin Registry
(http://ki.se/en/research/the-swedish-twin-registry).
Genotyping
DNA preparation from phase 2 cases. For iDILIC
cases, DNA was prepared as described previously.8 DILIN DNA
was extracted from lymphocytes and stored at the National
Institute of Diabetes and Digestive and Kidney Diseases
biosample repository at Rutgers University, Piscataway, NJ.
Genome-wide analysis. Genome-wide genotyping of
the phase 2 and 150 phase 1 cases was performed by the Broad
Institute, Boston, MA by Illumina Infinium HumanCoreExome
BeadChip. iDILIC and DILIN cases were genotyped in 2 separate
batches. A total of 505,740 markers shared across the batches
passed quality control and no samples were excluded for low-
quality profile (see Supplementary Materials and Methods).
Details on the genotype data available for each control
collection are reported in Supplementary Table 2.
Imputation. SNP imputation was performed in batches
dividing the cohorts according to genotyping platforms. Impu-
tation methods are described in detail in the Supplementary
Material. For HLA genotypes, 4-digit HLA alleles were
inferred using HIBAG.21
Single nucleotide polymorphism genotyping. The
top associated imputed SNPs were validated by SNP genotyping
in subsets of iDILIC cases and in the overall DILIN cohort (see
Supplementary Material). The SNPs were further confirmed in
additional cases using TaqMan predesigned and custom SNP
genotyping assays (ThermoFisher Scientific, Waltham, MA) in
accordance with the manufacturer’s recommendations.
HLA genotyping. High-resolution genotyping of HLA-A,
B, C, DRB1, DQA1, and DQB1 was performed on selected cases
by Histogenetics (Ossining, NY). Sequencing data files were
analyzed using Histogenetics’ proprietary analysis software
(Histomatcher and HistoMagic) for HLA genotype calling. Allele
assignments are based on IMGT/HLA Database release version
2.21.0, dated April 2008 (http://www.ebi.ac.uk/imgt/hla/).
Statistical Analysis
The effect of population structure was assessed through
principal components analysis using the smartPCA program
from the EIGENSTRAT package (version 3.0).22 Single marker
and haplotype association analyses and heterogeneity test
analyses were carried out by PLINK.23 The statistical associa-
tion of each marker, HLA alleles and SNPs, was determined in a
logistic regression framework with scores for the first 7 prin-
cipal components as covariates under an additive model using
PLINK. We used the same statistical test for subpopulation
analyses, using 2, 7, and 10 most significant principal compo-
nents as covariates in Italian, Spanish, and North European
populations, respectively. We set the genome-wide traditional
significance P-value threshold to 5.0  108 to correct for
multiple testing.24 When we obtained genome-wide significant
signals, we tested for independent effects from the neighboring
variants by including the most associated variants as a covar-
iate and then testing the significance of others in the region. We
also tested interaction effects among them by including inter-
action terms in the logistic regression. Differences in clinical
characteristics among sample groups were tested by Fisher’s
April 2017 GWAS on Liver Injury, Polymorphisms in HLA 1081exact test. All detailed analyses and Manhattan plots were
performed with R (version 3.0.2, The R Project for Statistical
Computing, http://www.r-project.org). Regional plots were
drawn by LocusZoom.25AL
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Clinical Characteristics of the Cases
Clinical details of the DILI cases included in the main
GWAS are summarized in Table 1. A variety of different
causative drugs were represented but the most common
was diclofenac with 67 cases, followed by nitrofurantoin
with 64 cases. A few drugs, including azathioprine, isoniazid,
fenofibrate, and diclofenac had significantly dispropor-
tionate number of cases in 1 of the 2 recruitment phases.
Details of all the causative drugs are shown in
Supplementary Table 3.CL
IN
ICOverall Analysis
The discovery cohort included 862 European ancestry
DILI cases (411 from phase 112 and 451 from phase 2) and
10,588 controls. Principal components analysis showed that
all cases (including those from South America) clustered
within 3 major groups (Italian, Spanish, and Northern
European) and matched with the population controls
(Supplementary Figure 1A). Consistent with the previous
study,12 phase 1 cases were predominantly NorthwestTable 1.Clinical Details of the Drug-Induced Livery Injury Case
Characteristic Phas
Clinical information
Mean age, y
% Female, %
Mean alanine aminotransferase, IU/L
Mean alkaline phosphatase, IU/L
Mean latency, d
Injury type
Cholestatic
Hepatocellular
Mixed
Not availablea
Genotype chip
Illumina 1 M
Illumina 1M/Illumina Infinium HumanCoreExome BeadChip
Illumina Infinium HumanCoreExome BeadChip
Illumina HumanOmniExpress BeadChip
Country of birth
United States
United Kingdom
Spain
Sweden
France
Germany
Italy
Other
aBecause of the retrospective nature of the phase 1 study, min
were not available for a subset of initial nonsteroidal anti-inflamm
of missing alkaline phosphatase and upper limit of normal valuEuropean. The most significant genome-wide associated
SNPs were rs72631567 on chromosome 2 (odds ratio [OR],
2.0; 95% confidence interval [CI], 1.62.5; P ¼ 9.7  109)
and rs114577328 in the MHC region of chromosome 6 (OR,
2.7; 95% CI, 1.93.8; P ¼ 2.4  108) (Figure 1A, Table 2,
and Supplementary Figures 2 and 3). Data for both SNPs
had been obtained by imputation in cases and controls and
subsequently validated by SNP typing (see Supplementary
Methods). The associations were consistent among
geographic clusters and study phases (Supplementary
Table 4) and not due to artifact(s) of population structure,
missing genotypes rate (Supplementary Table 5) or
variability in imputation quality among populations or
genotyping platforms (see Supplementary Methods).
For the chromosome 2 SNP rs72631567, breakdown by
drug showed that 10 unrelated drug causes had an OR >2.0
with at least 2 carriers (Supplementary Table 6).
Ciprofloxacin-related cases showed the strongest associa-
tion (n ¼ 21; OR, 7.4; 95% CI, 17.3161; P ¼ 4.0  106).
The chromosome 6 SNP rs114577328 is the SNP proxy
of an uncommon HLA class I allele, HLA-A*33:01. Indeed,
this SNP was in near-perfect linkage disequilibrium with
A*33:01 (r2 ¼ 0.98). From the imputed HLA allele assign-
ments, a strong association with DILI for this allele is
confirmed (OR, 2.6; 95% CI, 1.83.7; P ¼ 8.0  108,
Supplementary Figure 4). Including rs114577328 or
A*33:01 as a covariate removed any association in the MHC
region, indicating that there is only 1 MHC association signals Included in the Genome-Wide Association Study
e 1 (n ¼ 411) Phase 2 (n ¼ 451) Combined (n ¼ 862)
51 54 53
63.0 60.5 61.8
895.1 757.7 822.2
388.2 282.5 330.6
201.7 177.4 188.2
76 87 163
202 272 474
69 91 160
64 1 65
261 261
150 150
447 447
4 4
274 112 386
71 79 150
16 95 111
81 81
30 7 37
20 20
16 1 17
4 56 60
imal clinical information needed to establish the type of injury
atory druginduced liver injury cases from DILIGEN because
es.
Figure 1.Manhattan plots displaying the association results of (A) the overall analysis (n ¼ 864); (B) terbinafine only cases
(n ¼ 14 cases). SNPs in green have a significance level <5  106 and red have a significance level <5  108.
1082 Nicoletti et al Gastroenterology Vol. 152, No. 5
CLINICAL
LIVER(Supplementary Figure 5). The A*33:01 association appears
independent of the chromosome 2 signal, because
rs72631567, when conditioned on A*33:01, showed an
almost unchanged effect size (ORrs72631567, 1.7; 95% CI,
1.252.2; P ¼ .0006). There was no statistically significant
interaction effect between the 2 signals (P ¼ .5).
Breakdown by drug showed DILI due to terbinafine was
most strongly associated with the HLA-A*33:01 signal (OR,
40.5; 95% CI, 12.5131.4; P ¼ 6.7  1010) and a similarly
strong association was seen with rs114577328 (OR, 58.7;
95% CI, 18.31188.2; P ¼ 7.3  1012; Figure 1B and
Supplementary Figure 6). As summarized in Table 3, in
addition to terbinafine cases, cases due to 6 additional drugs
showed an association with A*33:01 with P < .01. The
largest case subset related to terbinafine, but we found that
A*33:01 was also a risk factor for ticlopidine (OR, 163.1;
95% CI, 16.21642.0; P ¼ .00002), methyldopa (OR, 97.8;
95% CI, 12.3743.0; P ¼ .00001) and fenofibrate DILI (OR,
58.7; 95% CI, 12.3279.8; P ¼ 3.2  107). Indeed,
although fewer positive carriers were observed, A*33:01
also seems to be a common risk factor for enalapril (OR,
34.8), sertraline (OR, 29), and erythromycin DILI (OR, 10.2).
An erythromycin case was positive for A*33:03, an allele
rare in European population controls (allele frequency [AF],
0.002) which belongs to the A*33 group. Overall, we found
that 87% (n ¼ 36) of the A*33:01-positive carriers were
also positive for HLA-B*14:02 and HLA-C*08:02. The
haplotype showed a larger OR than A*33:01 as single
marker in terbinafine (ORhaplotype, 49.2; P ¼ 9.54  1011),ticlopidine (ORhaplotype, 201; P ¼ 7.2  106), fenofibrate
(ORhaplotype, 68.5; P ¼ 1.1  107), and erythromycin
(ORhaplotype, 13.1; P ¼ .002) DILI, but not with DILI as a
phenotype (ORhaplotype, 2.7; P ¼ 1.6  107; Supplementary
Table 7).
We verified the imputed A*33:01 genotype by sequence-
based HLA typing in 35 cases related to the main A*33:01-
associated drugs (Supplementary Table 8). The A*33:01
predictions were confirmed in all cases except that one
methyldopa case was negative for this allele (false positive)
and an additional terbinafine case was a carrier (false
negative). This validation result suggests that methyldopa
might not share the HLA risk factor. The validation
confirmed that all the A*33:01-positive terbinafine cases
carried the complete HLA A*33:01-B*14:02-C*08:02 haplo-
type, increasing the strength of the haplotype association in
the terbinafine DILI cases (ORhaplotype, 70; P ¼ 8.7  1013)
and in the overall analyses (ORhaplotype, 2.8; P ¼ 5.1  108).
We also typed the A*33:01 proxy SNP across DILIN cases to
confirm imputed genotypes. We found only one new carrier
of the minor allele, not related to the major-A*33:01
associated drugs.Analysis by Type of Injury and Causative Drugs
We further investigated the association of genotypes
with particular patterns of DILI by grouping the cases into
hepatocellular (HC) and cholestatic/mixed (CM) pattern.
The chromosome 2 association described was similar in the
Table 2.Association Effect Size of rs72631567, A*33:01, and rs28521457 Across Different Liver Injury Patterns
Cohort Associated variant OR 95% CI P value AF cases AF controls
Entire DILI cohort rs72631567 2.0 1.62.5 9.7  109 0.05 0.03
A*33:01 2.6 1.83.7 7.0  108 0.02 0.01
rs28521457 1.5 1.31.9 5.1  105 0.06 0.04
Cholestatic and mixed DILI cohort rs72631567 2.4 1.73.4 9.5  107 0.06 0.03
A*33:01 5.0 3.37.9 4.2  1013 0.04 0.01
rs28521457 1.0 0.71.5 .9 0.04 0.04
Hepatocellular DILI cohort rs72631567 1.6 1.22.3 2.5  103 0.04 0.03
A*33:01 1.5 0.82.6 .19 0.01 0.011
rs28521457 2.1 1.62.7 4.8  109 0.08 0.040
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cases vs HC cases; logistic P ¼ .5), although the effect was
marginally stronger in the CM cases (Table 2). The associ-
ation with rs114577328 was genome-wide significant only
in the CM cases (n ¼ 323; OR, 5.3; 95% CI, 3.48.2; P ¼
4.5  1014; Figure 2B and Supplementary Figure 6) and
similarly with A*33:01 (OR, 5.1; 95% CI, 3.37.9; P ¼ 4.2 
1013; Figure 2B and Supplementary Figure 6). Conditional
analysis on the variant and HLA allele indicated only one
genetic association was present in the region, as shown for
the main analysis (Supplementary Figure 7). There was no
association between the proxy SNP or A*33:01 in the HC
cases (n ¼ 474; OR for A*33:01, 1.5; 95% CI, 0.822.6; P ¼
.19; Table 2). The A*33:01-B*14:02-C*08:02 haplotype
showed an ORhaplotype, 5.6; P ¼ 2.5  1013 in CM cases.
The CM only terbinafine-specific OR increased 2-fold
compared with the value for all terbinafine cases (OR,
88.1, 95% CI, 19.3402.4; P ¼ 7.5  10L9) because all the
A*33:01 carriers belonged to this injury type. Following the
injury correlation pattern established for terbinafine,
A*33:01 appeared to be a stronger risk factor for CM injury
than for HC injury also for fenofibrate, ticlopidine, enalapril,
and erythromycin-related DILI. This was not the case for
injury due to sertraline and methyldopa. These top 7 drugs
account for 51% (n ¼ 21) of all A*33:01 positive cases
(Supplementary Table 9). Sixteen other drugs account for
the rest of the carriers showing slight enrichment in CM
phenotypes, which showed a marginal association with
A*33:01 (OR, 2.6; 95% CI, 1.44.9; P ¼ .003)
(Supplementary Tables 9 and 10).Table 3.Association Effect Size of A*33:01 Signal for the Caus
Druga No. of cases tested No. of A*33:01 alleles
Ticlopidine 5 4
Methyldopa 4 2
Fenofibrate 7 4
Terbinafine 14 6
Enalapril 4 2
Sertraline 5 2
Erythromycin 10 2
CF, carrier frequency.
aCausal drug involved.We detected a new HC-specific genome-wide significant
signal on chromosome 4 (Figure 2B). The signal lies within
the LRBA gene with the imputed variant rs28521457,
located in an intronic region, the most significant SNP (OR,
2.1; 95% CI, 1.62.7, P ¼ 4.8  109) (Table 2 and
Figure 2B). The AF for this SNP in the CM cases (AF, 0.04)
was comparable to that in controls with no evidence of
association with this phenotype. The risk allele was carried
by >4% of the HC cases in cases due to a total of 45 drugs,
but in general, there were no drug-specific signals
(Supplementary Table 11).
We also investigated associations with particular caus-
ative drugs or specific therapeutic classes where a group
including more than 40 samples was available. Detail on the
groups studied is summarized in Supplementary Table 12.
Genome-wide significance was detected only for one group
examined, the statins, with no significant signals for the
other drug classes (Supplementary Figure 8 and
Supplementary Table 13). In the case of the statins,
rs116561224, a common intergenic SNP on chromosome
18, was genome-wide significant (OR, 5.4; 95% CI, 3.09.5;
P ¼ 7.1  109; Figure 2C and Supplementary Figure 9)
with the signal mainly driven by simvastatin
(Supplementary Table 14).Confirmation of Associations
The European cohort used to confirm the associations
(n ¼ 283) had a wider range of causal drugs, mostly
different from the discovery cohort (Supplementaryal Drugs Enriched in A*33:01-Positive Carriers
in cases OR 95% CI P value CF
163.1 16.21642 .00002 0.8
97.8 12.8743.8 .00001 0.5
58.7 12.3279.8 3.2  107 0.43
40.5 12.5131.4 6.7  1010 0.43
34.8 3.9302.9 .001 0.5
29 4207.2 .0008 0.4
10.2 251.7 .005 0.2
Figure 2.Manhattan plot displaying the association results for (A) cholestatic/mixed only cases (n ¼ 323); (B) hepatocellular
only cases (n ¼ 474 cases); (C) statin cases (n ¼ 59). SNPs in green have a significance level <5  106 and red have a
significance level <5  108.
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relating specifically to the statin cohort.
The A*33:01 association was further investigated in the
additional cases by directly genotyping rs114577328 in 272
cases and by direct HLA typing on 11 additional samples
who developed DILI due to drugs for which we had detected
an enrichment in A*33:01 alleles in the discovery cases.
Overall, the rs114577328 carriers were enriched in cases
from drugs previously associated with the allele
(Supplementary Table 15). Eight of all 23 additional cases
relating to drugs previously associated with A*33:01 were
shown to carry this allele or the proxy SNP (AF, 0.17)
compared with an expected population frequency of 0.01.
We specifically confirmed the association of A*33:01/
rs114577328 with terbinafine having a carrier frequency of0.63 (5 of 8 terbinafine-related cases across both the injury
types) and with sertraline at a carrier frequency of 0.75
(3 of 4 sertraline-related cases) (Supplementary Table 15).
Although fenofibrate had a high carriage rate for A*33:01 in
the discovery cohort, none of the 7 additional cases carried
this allele or the proxy SNP. Few additional cases were
available for other A*33:01-related drugs to confirm the
association.
Interestingly, a terbinafine DILI case from Finland was
positive for A*33:05, a very rare allele in the general Euro-
pean population (AF, 0.0001, USANMDPEuropean Caucasian
in http://www.allelefrequencies.net/; n ¼ 1,242,890) and
Finnish26 populations. An additional terbinafine DILI case of
Chinese origin was positive for A*33:03. In total, 10 of the 24
additional cases (23 European cases and 1 Chinese case)
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based on the effects observed in the discovery sample.
We further genotyped rs72631567 and rs28521457 in
272 additional European cases. The rs72631567 and
rs28521457 variants were found at AFs comparable to
those for controls (AFrs72631567, 0.022 and AFrs28521457 in
HC only, 0.025) and so the association was not confirmed.
However, rs72631567 carriers were slightly enriched in
ciprofloxacin, atorvastatin, and mercaptopurine-induced
DILI cases, as in the discovery cohort, with ORs in the
same direction in both cohorts (Supplementary Table 16).
Similarly, rs28521457 carriers seemed to be more common
in the same subgroup of causal drugs in both cohorts
(Supplementary Table 17). This suggested a limited
replication of the signal for these drugs.
We also attempted to confirm the rs116561224 signal
for statins. The number of additional cases available for this
purpose was small (n ¼ 29, Supplementary Table 1B) with
only 4 simvastatin cases. None of the statin cases were
positive for rs116561224 so the signal could not be
confirmed.Discussion
Our previous studies have been successful in identi-
fying genetic risk factors for both flucloxacillin and
amoxicillin-clavulanate DILI.4,6 However, our most recent
GWAS did not identify any risk factors that were common
for DILI in general or specific genetic risk factors for DILI
due to individual drugs, which accounted for a smaller
number of cases of DILI.12 The current study included 451
additional cases of DILI due to a wide variety of causative
drugs, including at least 10 DILI cases relating to each of
22 different drugs. This increase in numbers and the
exclusion of the amoxicillin-clavulanate and flucloxacillin
cases together with use of improved imputation methods
has enabled the detection and confirmation of a novel
genome-wide significant signal relating to a relatively rare
HLA class I allele A*33:01. Although 3 other interesting
signals were detected in the course of the study, an
intergenic signal on chromosome 2, an intronic SNP in
LRBA in HC cases only and a signal on chromosome 18 for
statins, the failure to confirm these signals is a limitation.
There are some indications that, as observed for
HLA-A*33:01, the chromosome 2 and LRBA signals are
shared across multiple unrelated drugs instead of being
nondrug-specific risk variants. As supporting evidence,
the chromosome 2 signal has been consistently associated
in both replication and discovery cohorts with DILI due to
ciprofloxacin, atorvastatin, and mercaptopurine. There
remains a possibility that replication could be achieved in
a larger study involving a different mix of causative drugs,
but the degree of heterogeneity in drugs originally
associated with the signals also increases the risk that
these were chance observations.
Interestingly, unlike previously recognized HLA associ-
ations for DILI, A*33:01 also appears to be a risk factor for
DILI due to several, structurally unrelated drugs. Our results
also suggest that a haplotype comprising A*33:01, B*14:02,and C*08:02 may participate in concert to confer risk for
DILI, as opposed to A*33:01 alone. However, because these
alleles are so highly correlated, our current sample size does
not allow us to distinguish between these possible expla-
nations by genetic association evidence alone. This
conceivable hypothesis could be further verified in a larger
study, or by experiments with recombinant HLA proteins.27
In the case of terbinafine where the A*33:01 association
showed genome-wide significance for cases relating to this
drug only, information on the underlying mechanism for
hepatotoxicity is limited, N-dealkylation leads to the for-
mation of an aldehyde metabolite, TBF-A, and this metabo-
lite shows reactivity with glutathione.28 It has been
proposed that the glutathione-adduct is transported across
the canalicular membrane and concentrated in the bile,
where it can cause damage to biliary epithelial cells. There
are limited data from the various case reports on an
underlying inflammatory mechanism, but it has been
demonstrated that treatment of monocytes with terbinafine
results in the release of the proinflammatory cytokines
interleukin 8 and tumor necrosis factora.29 Metabolism of
terbinafine is complex involving several different cyto-
chromes P450.30 However, there was no evidence from the
GWAS for a role for either CYP genes or innate immunity
genes in the terbinafine DILI cases studied.
The other drugs showing the most convincing associa-
tions with A*33:01 were fenofibrate, ticlopidine, and
sertraline. Failure to see individual genome-wide signifi-
cant associations with these drugs is likely to be due to
fewer cases being available than for terbinafine. The
A*33:01 association was seen for 3 of 7 cases due to
fenofibrate, all with CM DILI. The literature on fenofibrate
DILI is quite limited, but it appears that this drug is
extensively metabolized, mainly by CYP3A4,31 and there is
a report of a drug interaction resulting in cholestatic
injury32 together with other isolated reports of idiosyn-
cratic cholestatic DILI.33
Ticlopidine-related DILI has been well studied previ-
ously, including 2 studies investigating genetic risk factors
in Japanese individuals. Cholestatic liver injury also pre-
dominates in this form of DILI.34,35 Ticlopidine is subject to
extensive metabolism by several cytochrome P450 isoforms
and carboxyesterase.36 A study in rats suggests that adducts
are formed after metabolism by cytochrome P450 with
evidence for toxicity after biliary excretion of glutathione-
conjugated metabolites via MRP2-facilitated transport.37 In
previous studies, 22 Japanese patients with ticlopidine DILI
showed an association with an HLA haplotype including
A*33:03 (OR, 13).38 In line with current observations, the
association was strongest with cholestatic cases with 12 of
14 cases positive for A*33:03. It should be noted that
A*33:03 is relatively common in Japan with approximately
10%15% of individuals carrying this allele.
The observations on the HLA association for Japanese
ticlopidine DILI cases were followed up by a report that
those carrying a 2320T>C polymorphism in CYP2B6 were
more susceptible to ticlopidine DILI due to high CYP2B6
expression (OR, 2; P ¼ .04).39 The CYP2B6 polymorphism
(rs7254579)40 is less frequent in Europeans than in Asians
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size limited our ability to replicate the association in this
small European ticlopidine DILI population, but the
nonsignificant effect is in the same direction as the previous
study (OR, 2.8; 95% CI, 0.710.18; P ¼ .11).
In contrast with these 3 drug examples, sertraline is
associated predominantly with HC DILI.41–43 In line with
this phenotypic association, there is evidence that sertraline
can cause mitochondrial damage and induce endoplasmic
reticulum stress in liver cells.44 There are parallels with a
previous example of an HLA risk factor (DRB1*15:01) that is
associated with predominantly CM DILI with amoxicillin-
clavulanate, but HC DILI with lumiracoxib.9,10
In line with the Japanese report of a role for A*33:03
in ticlopidine DILI38 and a case report showing an asso-
ciation between A*33 and tiopronin-induced cholestasis in
a Chinese patient,45 we found 2 DILI cases positive for
A*33:03 after direct HLA typing. One of these was a
Chinese terbinafine DILI case and the second a European-
American with erythromycin DILI. In our imputed GWAS
data set, A*33:03 was carried by 8 DILI cases due to a
range of drugs in our cohort and showed an apparent risk
effect for CM DILI but this was not genome-wide signifi-
cant (OR, 2.1; 95% CI, 1.024.6; P ¼ .04). Another A*33
allele, A*33:05, was also represented in a terbinafine case
from Finland. There is very strong homology between
these 3 HLA-A*33 alleles at the protein sequence level
with A*33:03 differing at only 2 positions from A*33:01
(Tyr instead of His at position 171 and Lys instead of Arg
at position 186) and A*33:05 differing at only 1 position
(Arg at 54 in place of Gln). In particular, all 3 alleles
conserve the key residues for specific peptide binding
within the B and F pockets.46 This is in contrast to a
related HLA allele A*31:01, which is associated with
carbamazepine-induced skin rash,47 but does not appear
to be a risk factor for DILI, where the B pocket sequence,
though homologous, is not conserved.46
As mentioned, the association of a common HLA allele
with DILI due to chemically unrelated compounds had
been observed previously for DRB1*15:0110 with
amoxicillin-clavulanate and lumiracoxib and for
DRB1*07:0148 with DILI from lapatinib and ximelagatran.
The association of A*33:01 with DILI in general and sec-
ondary to a number of structurally dissimilar compounds is
consistent with these observations. Together with recent
findings from in vitro studies on T-cell responses to
flucloxacillin and amoxicillin-clavulanate,49,50 these obser-
vations support the hypothesis that either the parent drug
or metabolites bind covalently to cellular or circulating
proteins to form adducts in a mechanism that is probably
slightly different from the direct drug effect seen with
hypersensitivity reactions to abacavir.51 Adduct formation
may then allow binding to the peptide binding groove of
HLA molecules, leading to activation and differentiation of
T cells with a consequent adaptive immune response-
mediated liver injury. Evidence that the majority of the
drugs showing the A*33:01 association undergo hepatic
metabolism and biliary excretion may explain the stronger
association of A*33:01 with CM DILI and could indicatethat, unlike in the case of flucloxacillin and amoxicillin-
clavulanate, metabolites contribute to the toxicity mecha-
nism. Further investigation of potential interaction of both
the various drugs and their metabolites with the A*33:01
gene product by molecular modeling and in vitro studies
on T cells as undertaken previously for flucloxacillin49
would be of interest.
The novel association of HC DILI with LRBA is interesting
because this gene is a biologically plausible DILI candidate.
LRBA deficiency due to rare mutations is associated with
primary immunodeficiency of variable severity with a
particular feature of decreased regulatory T cell levels,
other immunodeficiencies, and inherited autoimmune
disease.52–55 Patients with mutations in LRBA leading to
immunodeficiency have been demonstrated to show loss of
cytotoxic T lymphocyte antigen4.56 Studies in a mouse
model suggest that low CTLA4 is a risk factor for DILI.57
Unlike the HLA-A*33:01 association, no genome-wide
significant associations for single drugs were detected
with the LRBA SNP, and there were no obvious features in
common between cases positive for the variant other than
the HC phenotype. It remains possible that this association
could be replicated if a larger cohort were available.
The intergenic signal on chromosome 2 is from a region
800 kb upstream from SOX11, is independent of A*33:01 and
associated with an almost 2-fold risk of DILI, with the top
SNP showing a frequency of 0.02 in Europeans. This risk
factor seems to be shared across unrelated drugs, among
which ciprofloxacin showed the strongest association. The
ENCODE project suggests there are no regulatory elements
in this region so the basis for the signal is unclear.
Neither rs72631567 nor any of its linkage disequilibrium
SNPs (r2 > 0.5) are known expression quantitative trait loci
variants (http://www.gtexportal.org/). The failure to
confirm this association and the absence of any apparent
biological basis suggests the observed significance could
have been a chance finding.
Most data for individual drug classes that were
comparatively well represented in our cohort were entirely
negative, but the finding of a signal for statins that was
driven by several class members was entirely novel. Similar
to the more general signal seen on chromosome 2, the
chromosome 18 is intergenic with the closest known gene,
cadherin 19, located approximately 300,000 bp down-
stream. Although functionally such a protein could be of
relevance to the liver injury process,58 any biologic signifi-
cance seems tenuous. The failure to confirm the signal in
additional cases could be due to the availability of only a
small cohort of additional cases, which reflects the rarity of
this form of DILI.59
In conclusion, this study has detected a novel HLA
association (HLA-A*33:01) in cases of DILI due to a number
of different drugs, together with several novel non-HLA
signals. Overall sensitivity and specificity of the A*33:01
allele as a predictor of DILI is low, but our findings may be
important for future drug treatment in cases of DILI due to
one of the drugs for which the A*33:01 association is
relevant. Follow-up studies are required to further explore
the intergenic signal on chromosome 2, the biologically
April 2017 GWAS on Liver Injury, Polymorphisms in HLA 1087interesting signal in LRBA, and the rs116561224 signal for
statins in larger cohorts.Supplementary Material
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